Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of Intravenous BNZ-1 in Patients With Moderate to Severe Alopecia Areata
In the register
The register attaches this trial to EQ101 (BNZ-1) (Equillium), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Withdrawn
- Declared phase
- Phase 2
- Sponsor
- Equillium
- Participants (registry)
- —
- Start
- October 2021 (planned)
- Primary completion
- November 2022
- Study completion
- November 2022
- Last registry update
- September 2022
- Countries
- —
Conditions studied: Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions: BNZ-1, Normal saline
Other trials of EQ101 (BNZ-1)
Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.